Study of Liver Function Tests in Newly Diagnosed Type II Diabetic Patients and Its Relation with Smoking as a Risk Factor
Article Sidebar
Main Article Content
Abstract
Diabetes mellitus ( DM ) stay as disease that can affect function of many organs and body’s systems. The liver is one of the organs that are adversely influenced by diabetes mellitus, so the current research aimed to study some liver enzymes which correlated to liver functions in newly diagnosed type II diabetes patients compared with healthy adults and its relation with smoking as a risk factor. In the present study the tests of liver function were represented as (Aspartate aminotransferase (AST) , Alanine aminotransferase (ALT) , Alkaline phosphatase (ALP) in addition to De Ritis Ratio) measured in blood samples of 45 newly diagnosed type II diabetic patients (24males&21females) which divided into two subgroups according to smoking habit; the first include 17 smoker diabetic patients, the second include 28 non smoker diabetic patients. The control group included 42 healthy non smoker volunteers, to assess the association between some liver function biochemical parameters such as ALT, AST, ALP and De Ritis Ratio in newly diagnosed type II diabetes in a Mosul population; in addition to finding the gender & smoking effects on these hepatic enzymes. According to measured results in this current research, a major elevation in enzyme activity of (ALT, AST, in addition to ALP) was noticed in diabetic patients in comparison with non˗ diabetic control, as well as, there is a significant effect of smoking in smokers group of patients in comparison with non- smokers diabetic group and control group. While non significant effect noticed in the sera hepatic enzymes mean (ALT&AST) and (ALP) activit of male & female diabetics. Lastly, the outcomes of the De Ritis Ratio established that non significant alteration in every one comparison in this study.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Mohd S, Kumar L L, Harish V, Kumar R, Chaudhary A, Sharma V. Diabetes mellitus: Complications, emerging therapeutic targets, and evolving treatment approaches. Obesity Medicine.2025, 58100652,
https://doi.org/10.1016/j.obmed.2025.100652.
Alanazi S M, Alasad S M, Alqabi M M A, Alqabi M M A, Alruwaila A M A, Alruwaila O M A, Mahnasi S A A. Diabetes Mellitus: Pathophysiology, Insulin Resistance, Nutritional Care, and Nursing Implications . Journal of International Crisis and Risk Communication Research . 2024, 33–52. https://doi.org/10.63278/jicrcr.vi.278
Mahmoud MR, Ibrahim S, Shahien MM, Alshammari AD, Alenazi FS, Alreshidi F, Aljadani A, Abdel Khalik A, Elhaj AH, Khalifa AM, et al. Comparison Between the Impact of Diabetes Mellitus on Liver Diseases and Vice Versa Among Saudi and Egyptian Patients. Healthcare. 2025; 13(4):376. https://doi.org/10.3390/healthcare13040376
Yameny A. Diabetes Mellitus: A Comprehensive Review of Types, Pathophysiology, Complications, and Standards of Care in Diabetes 2025, Journal of Medical and Life Science. 2025, 7(1), pp. 134-141. doi: 10.21608/jmals.2025.424001
Aamodt KI, Powers AC. The pathophysiology, presentation and classification of Type 1 diabetes. Diabetes Obes Metab. 2025 Aug;27 Suppl 6(Suppl 6):15-27. doi: 10.1111/dom.16628.
Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J & Franczyk B. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. International Journal of Molecular Sciences. 2025, 26(3), 1094. https://doi.org/10.3390/ijms26031094
Yadav A, Yadav A, Yadav AK. A Review on Diabetes Mellitus
International Journal of Pharmaceutical Research and Applications. 2025; 10(2):2273. DOI:10.35629/4494-100222732280.
Riachi R, Khalife E, Kędzia A, & Niechciał E. Understanding Insulin Actions Beyond Glycemic Control: A Narrative Review. Journal of Clinical Medicine. 2025,14(14), 5039. https://doi.org/10.3390/jcm14145039
Riachi R, Khalife E, Kędzia A, Niechciał E. Understanding Insulin Actions Beyond Glycemic Control: A Narrative Review. Journal of Clinical Medicine. 2025; 14(14):5039. https://doi.org/10.3390/jcm14145039
Duan L, Chang Y, Dai J, Lu H, Zhao W, Shen Y, Lin J, Cai X. Lipid metabolism orchestrates liver regeneration: an integrated metabolic network. J Transl Med. 2025 Oct 16;23(1):1115. doi: 10.1186/s12967-025-07232-5.
Ma X, Huang T, Chen X, Li Q, Liao M, Fu L, Huang J, Yuan K, Wang Z, Zeng Y. Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics. Signal Transduct Target Ther. 2025 Feb 8;10(1):63. doi: 10.1038/s41392-024-02104-8.
Mruga D, Berketa K, Dzyadevych S, Soldatkin O, Biosensors for transaminase detection: Their diversity and trends – A comprehensive review. TrAC Trends in Analytical Chemistry.2025; 193:118460. https://doi.org/10.1016/j.trac.2025.118460.
AL-Hamdani IH. Evaluation of Sera Alanine aminotransferase, Aspartate aminotransferase and Alkaline phosphatase in Adult Obese Ninava People. Tikrit Journal of Pharmacological Science.2010; 6(1): 63-69.
AL- khaykanee AM, Hamad AG, and Hussein SA. A review about liver function tests. GSC Biological and Pharmaceutical Sciences. 2025, 30(01), 213-2172025. DOI:10.30574/gscbps.2025.30.1.0023
Gabeta S, Dalekos GN, Gatselis NK. Management of asymptomatic patients with abnormal liver function tests. Eur J Intern Med. 2025 Nov;141:106429. doi: 10.1016/j.ejim.2025.07.025.
Mehyar N, Alhajeri Z, Alosaimi M, Alanazi Z, Alanazi A, Abusaris R. The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study. Front Clin Diabetes Healthc. 2025 Jul 29;6:1617641. doi: 10.3389/fcdhc.2025.1617641. PMID: 40799261; PMCID: PMC12339336.
Shaikh SM, Varma A, Kumar S, Acharya S, Patil R. Navigating Disease Management: A Comprehensive Review of the De Ritis Ratio in Clinical Medicine. Cureus. 2024 Jul 13;16(7):e64447. doi: 10.7759/cureus.64447.
Javed A, Mehboob K, Rashid A, Majeed A, Ibrahim MI, Mushtaq I. Significance of sera ferritin and De Ritis ratio in non-alcoholic fatty liver disease as diagnostic markers. J Pak Med Assoc. 2024 Apr;74(4):656-660. doi: 10.47391/JPMA.9289. PMID: 38751257.
Reitman S, and Frankel S. A colorimetric Method for The Determination of Sera Glutamic Oxaloacetic and Glutamic Pyruvic Transaminases. Am. J. Clin. Pathol.1957;28:56.
Kind PRN, and King EJ. Estimation of Plasma Alkaline Phosphatase by Determination of Hydrolysed Phenol with Aminoantipyrine. J. Clin. Pathol.1954;7: 322.
De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase sera activities. Clin Chim Acta .1957, 2(1):70–4. doi: 10.1016/0009-8981(57)90027-x
Armitage P., and Berry G., Statistical Methods in Medical Research, 2nd ed. Blackwell, Oxford, London, UK. 1985.
Mathur S, Mehta DK, Kapoor S, Yadav S. Liver Function in Type-2 Diabetes Mellitus Patients. Int J Sci Stud. 2016;3(10):43-47.
Harris EH. Elevated liver function tests in Type 2 diabetes. Clin Diabetes.2005;23:3.
Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes.2002;51:1889-95.
Sheng X, Che H, Ji Q, Yang F, Lv J, Wang Y, et al. The relationship between liver enzymes and insulin resistance in type 2 diabetes patients with nonalcoholic fatty liver disease. Horm Metab Res.2018;50(05):397-402.
Music M, Dervisevic A, Pepic E, Lepara O, Fajkic A, Ascic-Buturovic B, et al. Metabolic syndrome and sera liver enzymes level at patients with type 2 diabetes mellitus. Med Arch.2015;69(4):251.
American Gastroenterological Association. Medical position statement: Evaluation of liver chemistry tests. Gastroenterology.2002;123:1364-1366.
Raja MM. Raja A. Imran MM. Santha AM. Devasena K. Enzymes Application in Diagnostic Prospects. Enzymes Application in Diagnostic Prospects. Biotechnology.2011;10:51-59.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hematology.2006;43:99-112.
AL-Hamdani I.H., Biochemical Changes of Sera Liver Enzymes (Aspartate aminotransferase, Alanine aminotransferase and Alkaline phosphatase) in Cigarette Smokers in Mosul. Tikrit Medical Journal. 2007; 13(2): 161-165.
Mohammed K. Elameen, AbdElkarim A. Abdrabo. Comparative Study of Liver Enzymes Activities in Smokers and Diabetic Sudanese Patients. Asian Journal of Biomedical and Pharmaceutical Sciences.2013;03(27):39-41.
Levinthal GN, Tavili AS. Liver disease and diabetes mellitus. Clin Diabetes.1999;17:2.
AL-Hamdani I H, and Al-Helaly L A. Peroxiredoxin 3 and Oxidative Stress in Recurrent abortion Patients. MMSL. 2023, 92(1), 87-94 DOI:10.31482/mmsl.2022.034.
El-Azab G, Elkhouly E, Abouyoussef R, Nagdy H. Smoking and liver diseases: an updated review of pathogenesis, progression, and therapeutic implications. Clin Exp Med. 2025 Dec 3;26(1):51. doi: 10.1007/s10238-025-01922-6. PMID: 41335258; PMCID: PMC12675660.
AL-Hamdani I H, and Al-Helaly L A. Peroxiredoxin 3 with Toxic metals in Missed Abortion Patients. MMSL. 2023, 92(3), 272-279. DOI: 10.31482/mmsl.2022.050
Batty M., Bennett M.R., Yu E. The Role of Oxidative Stress in Atherosclerosis. Cells. 2022;11:3843. doi: 10.3390/cells11233843